New drug combo shows promise in early breast cancer trial
NCT ID NCT01597388
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-phase study tested a new oral drug (AZD2014) combined with a standard hormone therapy (fulvestrant) in 99 people with advanced, ER+ breast cancer. The main goal was to check safety and how the body processes the drugs, not to cure the disease. Participants had to have at least one tumor that could be measured by scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sarasota, Florida, 34232, United States
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Oklahoma City, Oklahoma, 73104, United States
-
Research Site
Greenville, South Carolina, 29605, United States
-
Research Site
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.